Chantix Indication:

For use as an aid in smoking cessation.

Chantix Mechanism Of Action:

Chantix is an alpha-4 beta-2 neuronal nicotinic acetylcholine receptor agonist. The drug shows high selectiviyty for this receptor subclass, relative to other nicotinic receptors (>500-fold alpha-3 beta-4, >3500-fold alpha-7, >20,000-fold alpha-1 beta gamma delta) or non-nicotinic receptors and transporters (>2000-fold). The drug competitively inhibits the ability of nicotine to bind to and activate the alpha-4 beta-2 receptor. The drug exerts mild agonistic activity at this site, though at a level much lower than nicotine; it is presumed that this activation eases withdrawal symptoms.

Chantix Drug Interactions:

Not Available

Chantix Food Interactions:

Not Available

Chantix Generic Name:


  • Not Available

Drug Type:

Small Molecule; Approved


Not Available

Toxicity (Overdose):

Not Available

Protein Binding:

Less than 20%.


Metabolism is limited (<10%). Most of the active compound is excreted renally (81%). A small proportion is glucuronidated, oxidated, N-formylated or conjugated to a hexose.

Half Life:

The elimination half-life of varenicline is approximately 24 hours

Dosage Forms of Chantix:

Tablet, film coated Oral

Chemical IUPAC Name:

Not Available

Organisms Affected:

Humans and other mammals

Chantix to general, pharmacology

General, pharmacology..